Liver tumors near larger blood vessels present a specific technical challenge for thermal ablation: flowing blood can carry heat away from the treatment zone before it fully destroys the tumor tissue, an effect commonly known as the heat-sink effect. One strategy discussed in the interventional oncology literature to address this challenge is ablation plus embolization, a combination approach that pairs vascular occlusion techniques with radiofrequency or other thermal ablation methods. This article explains the general concept behind combining these treatments and where embolization devices fit into that picture.
Why Consider Combining Treatments Instead of Ablation Alone?
Tumors located close to major hepatic vessels can be harder to treat completely with ablation alone, because blood flowing through nearby vessels continuously carries heat away from the target area, potentially leaving a rim of viable tumor near the vessel even when the rest of the lesion is adequately treated. Reducing blood flow to the tumor before or during ablation is a strategy commonly reported in the literature as a way to potentially limit this heat-sink effect, since less flowing blood means less thermal energy is carried away from the treatment zone. This is generally discussed as a way to potentially allow for a more complete or larger ablation zone in tumors that would otherwise be difficult to treat with thermal energy alone, though outcomes vary by case and this approach does not guarantee complete tumor destruction in every patient.
What Is TACE Plus RFA and How Does It Generally Work?
One specific combination frequently discussed in liver tumor literature is transarterial chemoembolization performed alongside radiofrequency ablation, sometimes referred to as TACE plus RFA. Transarterial chemoembolization involves delivering chemotherapeutic agents directly into the tumor's blood supply along with an embolic material that blocks blood flow to the tumor, while RFA uses electrode-delivered radiofrequency current to generate heat within the tumor. When performed together, either in the same session or in a staged sequence, this combination is commonly reported in the literature as a way to address both the tumor's blood supply and its cellular destruction through two different mechanisms. The specific sequencing, timing, and whether this combination is appropriate for a given patient are determined by the treating multidisciplinary team based on tumor size, location, and the patient's overall liver function.
How Does Embolization Contribute to Flow Reduction?
Embolization broadly refers to intentionally occluding a blood vessel using various devices or materials, which is the flow reduction step in a combination strategy. Depending on the clinical scenario, embolic devices used in these procedures can include coils, particles, or self-expanding vascular plugs designed to occlude a targeted vessel. In the setting of transarterial radioembolization (TARE) or other embolization procedures relevant to liver tumor management, a self-expanding occlusion device such as the MultiBEAM Embolization Plug may be used by the treating physician as part of a broader vascular access and occlusion strategy. The manufacturer describes the MultiBEAM as a multisided, self-expanding nitinol plug designed for vascular occlusion with minimal migration, delivered via catheter and intended for indications including TARE, peripheral aneurysms, and other vascular occlusion needs, as stated by the manufacturer. Its role in any specific liver tumor case, including whether it is used alongside an ablation procedure, is determined by the treating interventional radiologist based on the individual patient's vascular anatomy.
How Is This Combination Approach Decided For an Individual Patient?
Whether to combine ablation with embolization, use either technique alone, or pursue a different treatment path altogether depends on tumor size, number, location relative to major vessels, and the patient's underlying liver function and overall health. This decision is typically made through multidisciplinary discussion among interventional radiologists, hepatologists, and oncologists, weighing the potential benefits of combination therapy against the added procedural complexity of performing two techniques rather than one. No combination approach can guarantee a specific outcome for an individual patient, and suitability is assessed on a case-by-case basis.
Devices Relevant to This Combination Strategy
The MultiBEAM Embolization Plug is one device relevant to the embolization component of this combination strategy; more detail is available on the MultiBEAM Embolization Plug product page. The ablation component draws on devices within INVAMED's broader oncology-ablation portfolio, which can be reviewed on the INVAMED oncology ablation products page.
Does combining ablation and embolization guarantee better tumor control than ablation alone?
No single combination guarantees a specific outcome for any individual patient. Combination approaches are discussed in the literature as a strategy to potentially address heat-sink limitations near vessels, but tumor biology, location, and patient-specific factors all influence the actual result, and this determination is made by the treating team.
Is TACE plus RFA performed in one session or over multiple visits?
Both staged and same-session approaches are described in the literature, and the specific sequencing depends on institutional protocol, tumor characteristics, and the patient's condition. The interventional radiology team determines the appropriate timing for a given case.
What types of devices are used for the embolization portion of combination therapy?
Embolization devices can include coils, particles, and self-expanding vascular plugs, among other options, selected based on the target vessel's size and anatomy. The choice of device is made by the treating physician according to the specific vascular occlusion needed.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.